Cheviot Value Management’s Novavax NVAX Stock Holding History

Cheviot Value Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15	Closed	-$94	–	453
2025 Q1	$94	Buy	+15	New	+$124	﹤0.01%	441

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cheviot Value Management's NVAX Position: Q2 2025 in Review

Cheviot Value Management sold out of Novavax (NVAX) in Q2 2025, closing a stake of 15 shares — an estimated $94 sold.

Cheviot Value Management first reported a position in NVAX in Q1 2025 and held it in 1 quarter. The position peaked at $94 in Q1 2025. 250 funds tracked by Wall St. Rank hold NVAX as of Q2 2025.

Cheviot Value Management reported no remaining Novavax position as of Q2 2025 after selling out during the quarter.
Cheviot Value Management sold 15 Novavax shares in Q2 2025, an estimated $94.
Cheviot Value Management first reported a position in Novavax in Q1 2025 and held it in 1 quarter.
Cheviot Value Management's Novavax position peaked at $94 in Q1 2025.
250 funds tracked by Wall St. Rank held Novavax as of Q2 2025.

Based on Cheviot Value Management's 13F filing for Q2 2025, filed 13 Aug 2025.